What Synulox L.C. Treats: Main Uses and Benefits

Synulox L.C. is commonly used for managing clinical mastitis in lactating cows by addressing conditions characterized by periods of heightened symptoms. This combination formulation is relevant in clinical settings that involve acute or unstable symptom patterns. Specifically, it is applied in situations involving bacterial pathogens, including Staphylococci, Streptococci, and E. coli, where the focus is on local symptom management.

This veterinary medicine is considered relevant for easing symptoms related to inflammatory or irritative states and physical discomfort. It is applied in scenarios where additional management of discomfort is required, such as in cases of acute inflammation, swelling, and sensitivity in the udder quarter. The medication may assist with easing these acute symptomatic manifestations, which contributes to improved comfort during periods of distress. As part of a comprehensive management strategy, it offers supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Symptom Management in Acute Episodes

This formulation is commonly used to help alleviate the physical signs associated with infection, supporting the management of swelling and heat in the affected tissue, and helps address symptom clusters that may become intense or disruptive.

Regulatory References

1. Summary of Product Characteristics from the Health Products Regulatory Authority

Who Can and Cannot Use Synulox L.C.?

Synulox L.C. is a specialized veterinary medicinal product whose eligibility is strictly defined by regulatory documents. The medicine is officially approved for use exclusively in cattle (lactating cows) for the treatment of clinical mastitis. Eligibility is determined by species and physiological state, meaning restrictions are based on the animal's status, not age.

---

Official Eligibility Constraints

The medicine is contraindicated and must not be used in animals with a known history of hypersensitivity to beta-lactam antibiotics, the active ingredients (Amoxicillin, Clavulanic acid, Prednisolone), or any of the excipients.

Furthermore, use is strictly prohibited in cases of mastitis associated with the bacterial genus Pseudomonas. The label also specifies that use should be avoided in herds where beta-lactamase producing Staphylococci strains have not been isolated.

For approved use, the official labeling dictates that the medicine must be used only for clinical mastitis, and its application should be guided by appropriate susceptibility tests. No special precautions are necessary for the animal during pregnancy.

Interactions with other medicines and products

The official interaction profile for Synulox L.C. Intramammary Suspension is defined by the regulatory finding that there are no known interactions with other medicinal products or substances. This status is derived from the formal documentation found in the Summary of Product Characteristics (SPC) issued by European and national health regulatory authorities.

As a locally applied veterinary medicine, its specific route of administration and resulting systemic exposure profile influence the official documentation of potential systemic drug interactions. The regulatory status of "None known" governs the information available in the official label.

---

Interaction Scope and Regulatory Classification

The official regulatory label does not list any specific interacting medicinal products or substance categories. Consequently, the label contains no documented information regarding the mechanistic basis of interactions, such as effects on hepatic cytochrome P450 (CYP) enzymes or drug transporters. Furthermore, the label does not specify any timing-based interaction rules requiring separation of administration from other veterinary medicines.

There are no population-specific interaction notes or formal contraindicated combinations documented for co-administration. The absence of documented interactions means the label contains no official restrictions related to exposure-modifying effects or pharmacodynamic interactions. This regulatory statement formally defines the limits of the product's official interaction profile.

How Synulox L.C. Works

Synulox L.C. exerts its effects through three distinct mechanisms involving its active components: amoxicillin, clavulanic acid, and prednisolone.

---

Cell Wall Synthesis Inhibition

Amoxicillin, a beta-lactam antibiotic, acts as a mechanism-based inhibitor. It binds to bacterial transpeptidases (often referred to as penicillin-binding proteins or PBPs) located on the outer surface of susceptible organisms. This interaction disrupts the transpeptidation step necessary for peptidoglycan cross-linking, which is essential for bacterial cell wall rigidity. This molecular cascade leads to the destabilization of the cell structure, culminating in osmotic imbalance and bacterial cell lysis.

---

Bacterial Defense Mechanism Modulation

Clavulanic acid is a suicidal beta-lactamase inhibitor. It targets and forms a stable covalent bond with the active site of bacterial beta-lactamase enzymes. These enzymes are defense mediators that hydrolyze and inactivate amoxicillin. By irreversibly binding the beta-lactamases, clavulanic acid prevents the enzymatic degradation of amoxicillin, allowing unimpeded interaction of amoxicillin with the PBP targets on the bacterial cell wall.

---

Anti-Inflammatory Mediator Suppression

Prednisolone, a corticosteroid, engages intracellular glucocorticoid receptors. This binding modulates gene transcription, resulting in the suppressed synthesis and release of various inflammatory signaling molecules, including prostaglandins and leukotrienes. This pathway modulation alters the physiological processes related to local vascular permeability and cellular infiltration.

How to Use Synulox L.C.: Official Administration Guidelines

This section summarizes the usage instructions for Synulox L.C. Intramammary Suspension, detailing the prescribed administration route, dosage, and frequency patterns.

---

Administration Scope

Category	Official Instruction
Route of Administration	Intramammary Use (Intracisternal) into the teat canal of the affected quarter.
Dosing Schedule	The standard dose is the full contents of one single syringe per affected udder quarter.
Timing in Relation to Milking	Administered immediately after the affected udder quarter has been completely milked out.
Preparation Requirements	The teat end must be cleaned and disinfected with an appropriate disinfectant prior to administration.
Course Duration	The standard regimen is three consecutive treatments, administered at 12-hour intervals.

---

Resulting Procedural Structure

The administration protocol outlines a precise sequence necessary for the correct use of the medicine, limiting its application to the affected quarter following specific preparation steps.

Official Step Sequence:

• Completely milk out the affected udder quarter.
• Clean and disinfect the teat end thoroughly.
• Infuse the entire contents of one single syringe into the teat canal.
• Gently massage the suspension upwards into the udder.
• Repeat the entire sequence in 12 hours for a total of three treatments.

---

Connection to the Overall Use Protocol

The instructions define a standardized and localized method of drug administration that utilizes the intramammary route exclusively. This protocol establishes a fixed single-syringe dose and a 12-hour frequency as the fundamental regimen for its use. The necessary procedural steps, including mandatory prior milking and aseptic technique, govern the context under which the medicine is to be used.

Synulox L.C.: Recent Clinical Evidence

Evidence Supporting Use in Clinical Mastitis in Lactating Cows

Research was studied for Synulox L.C. in managing clinical mastitis in lactating cows, particularly in cases involving periods of heightened symptoms. The Research evidence base consists primarily of Controlled Clinical Trials and Regulatory Efficacy Studies that evaluated outcomes related to physical discomfort and the microbiological status of the affected quarters. Studies explored the patterns observed concerning the association between the product's administration and measured outcomes related to observed symptoms and infection status. The component intended to address inflammation was evaluated in studies examining temporary physiological imbalance and the localized inflammatory response.

Types of Outcomes Examined and Duration of Evidence

The primary focus of the trials was the bacteriological cure rate, which research examined as the clearance of the specific pathogen. This measure contributes to understanding symptom patterns in the regulatory assessment. In addition to infection clearance, studies monitored the status of local inflammatory signs, such as udder swelling and abnormal milk appearance. These outcomes were relevant in trials assessing short-term or episodic symptom patterns. The Research evidence was studied for intermediate follow-up durations, typically 14 to 28 days post-treatment, which is the defined interval used in the research for primary outcome evaluation.

What is Still Uncertain About the Research for Synulox L.C.

Evidence is limited regarding long-term effects and the durability of the response; the long-term effects are not fully established. The research emphasis is concentrated on localized outcomes within the affected quarter. Comparative evidence is lacking regarding systemic effects or overall herd health over extended periods. For some pathogens, findings were mixed in the studies. Subgroup findings are uncertain due to limited data. The research does not determine whether an individual will respond similarly, and studies help show what has been observed so far in group patterns.

Key Studies & References Summary of Product Characteristics from the Health Products Regulatory Authority (HPRA) (Synulox L.C.)

Common questions about Synulox L.C. (FAQ)

---

Q: Is Synulox L.C. the same product as the Synulox prescribed for dogs?

No. According to regulatory documents, Synulox L.C. is a specialized intramammary suspension authorized exclusively for treating mastitis in lactating cows. It differs significantly from oral or injectable Synulox formulations intended for use in different animal species and health conditions. It also contains the anti-inflammatory prednisolone, which is not found in all other Synulox products.

---

Q: How is Synulox L.C. different from Synulox RTU injection?

The key difference is the route of administration. Synulox L.C. is an intramammary suspension for highly localized action directly within the cow’s udder. Synulox RTU is an injectable suspension intended for systemic, or whole-body, treatment in cattle and pigs.

---

Q: Is Synulox L.C. used for human infections?

No. Official regulatory documents classify Synulox L.C. as a veterinary medicinal product that is exclusively authorized for the treatment of clinical mastitis in cattle (lactating cows). It is not indicated for use in humans.

---

Q: How is the formulation of Synulox L.C. (intramammary suspension) different from other Synulox products?

Official information describes Synulox L.C. as a specialized, oily intramammary suspension for local use in cows, combining an antibiotic, a resistance inhibitor, and a corticosteroid (prednisolone). Other Synulox products for different species often come as oral tablets or drops and may not contain the anti-inflammatory component.

---

Q: Does the milk withdrawal period change if a cow is milked three times a day?

The required milk withdrawal period remains a fixed duration of 84 hours following the last treatment. Official guidance clarifies that for a three-times-a-day milking routine, this duration means milk for human consumption may be taken at the 11th milking after the final treatment.

---

Q: Can a person get an allergic reaction just from handling the syringe?

Yes, regulatory warnings indicate that penicillins can cause hypersensitivity (an allergy) following skin contact. Regulatory warnings state that individuals known to be sensitive to β-lactam antibiotics should avoid exposure and handle the product with care.

---

Q: What happens if the cow receives more than the recommended number of syringes? (Overdose query)

Regulatory documents include a specific statement on this matter. According to the official product information, no adverse reactions are expected from an accidental overdose of Synulox L.C.

---

Q: What official guidance is available regarding accidental overdose of Synulox L.C.?

Official regulatory information on the product’s safety profile explicitly states that no adverse reactions are expected from an accidental overdose.

---

Q: How is the medicine absorbed into the cow's udder? (Pharmacokinetics, allowed if answer is purely factual)

The medicine is formulated as a viscous, oily intramammary suspension. This formulation is a characteristic described in official documents as favoring the maintenance of high concentrations of the active substances at the localized site of application.

---

Q: What is the official classification of this drug (e.g., broad-spectrum)?

The product is officially classified as a broad-spectrum bactericidal β-lactam antibiotic (amoxicillin/clavulanic acid) combined with an anti-inflammatory corticosteroid (prednisolone).

---

Q: How long after the first dose might a person expect to see a change in the cow's quarter?

The product contains prednisolone, which is an anti-inflammatory component. This component is intended to address the localized inflammatory response. Clinical trials examine short-term symptom patterns related to this component.

---

Q: Why do some sources suggest a longer treatment course for Staphylococcus aureus?

Official guidelines explicitly indicate that a longer course of antibacterial therapy may be required in cases of infection caused by Staphylococcus aureus compared to the standard regimen. This recommendation is based on official protocols for treatment.

---

Q: Has the marketing authorisation for Synulox L.C. ever been reviewed by the EMA?

Yes. Official records show that the product's marketing authorisation was subject to an official review procedure by the European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP). This review concluded with a positive opinion in 2011.

---

Q: What are the known excipients (non-active ingredients) in the Synulox L.C. suspension?

Official product documentation lists the excipients (non-active ingredients). These include sodium aluminosilicate, cetostearyl alcohol, white soft paraffin, and light liquid paraffin.

How to Store and Dispose of Synulox L.C.

Official regulatory documents specify mandatory conditions for the storage and disposal of Synulox L.C. The product must be stored at a temperature not exceeding 25 C and kept in a dry place. The individual syringes must remain in the original outer carton until use to ensure stability and protection from light, particularly for the moisture-sensitive Clavulanic acid component.

For safety, the medication must be stored out of the sight and reach of children.

Disposal Guidelines

Any unused product or waste material must be disposed of in accordance with local requirements for pharmaceutical waste. The official instructions prohibit releasing the product or its containers into the environment, including discharging them into sewers or waterways.